ReviewZeitschrift fur Gerontologie und Geriatrie2026
Pathophysiology and biomarkers of delirium in older adults-Narrative review.
Review in Zeitschrift fur Gerontologie und Geriatrie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelirium is a frequent acute neurocognitive syndrome in older adults, associated with morbidity, mortality, and long-term cognitive decline. Its pathophysiology is multifactorial and not yet fully understood.
objectiveTo summarize clinically relevant concepts of delirium pathophysiology and emerging biomarkers.
methodsNarrative review of literature from 2010-2026, prioritizing human studies, reviews, meta-analyses, and clinically relevant pathophysiological literature relevant to older hospitalized or perioperative patients.
resultsDelirium arises from the interaction of predisposing vulnerability and acute triggers. Relevant mechanisms include neuroinflammation, neurotransmitter imbalance, neurodegeneration, metabolic dysfunction and blood-brain barrier impairment. Biomarker research has identified promising candidates, including inflammatory, neurodegenerative, metabolic and stress-related markers but none is currently established for routine clinical use.
conclusionDelirium prevention remains clinically driven. Multimodal biomarkers may support future risk stratification but require prospective validation.
Indexed as
Identifiers
42698026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.